METACARE CO., Ltd. (KRX:118000)
305.00
+3.00 (0.99%)
At close: Nov 26, 2025
METACARE CO. Revenue
METACARE CO. had revenue of 10.75B KRW in the quarter ending September 30, 2025, with 121.30% growth. This brings the company's revenue in the last twelve months to 28.10B, up 47.29% year-over-year. In the year 2024, METACARE CO. had annual revenue of 20.21B with 17.10% growth.
Revenue (ttm)
28.10B
Revenue Growth
+47.29%
P/S Ratio
1.86
Revenue / Employee
906.55M
Employees
31
Market Cap
52.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.21B | 2.95B | 17.10% |
| Dec 31, 2023 | 17.26B | -1.84B | -9.64% |
| Dec 31, 2022 | 19.10B | 484.98M | 2.61% |
| Dec 31, 2021 | 18.61B | 11.99B | 181.12% |
| Dec 31, 2020 | 6.62B | -49.53B | -88.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |